Peptide Research Hub
Educational reference
Educational reference only. Nothing on this site is medical advice. Many compounds described here are not FDA-approved, lack adequate human evidence, and may be illegal in your jurisdiction. Always consult a licensed clinician.

Nootropic & Neuropeptides

Cerebrolysin

Evidence: Moderate clinical Disclaimer: Elevated Approved in some countries; not FDA-approved
Elevated-disclaimer compound. Not approved by the FDA. Evidence is limited to animal models or small human studies. Safety in humans has not been established.

Mechanism & research context

Mixture of low-molecular-weight peptides from porcine brain tissue. Studied in dementia and stroke; approved in some European and Asian countries. Not FDA-approved.

Origin: Porcine brain-derived peptide extract.

Safety flags

0 flags

No curator-recorded safety flags for this entry. Absence of recorded flags is not evidence of safety. Many peptides lack adequate human data.

Research papers

16 records

Citation links route to PubMed, Europe PMC, and PMC. Presence of a study is not endorsement. Records are refreshed from PubMed on a regular cadence; rows marked “Live search link” will resolve to a current PubMed search until a full citation has been ingested.

Clinical trials

21 records
  • Live search Live search

    Live ClinicalTrials.gov search: Cerebrolysin

    Condition: See live results

    Open on ClinicalTrials.gov ↗
  • NCT00868283 PHASE4 COMPLETED

    A Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Safety and Efficacy of Cerebrolysin in Patients With Acute Ischemic Stroke

    Condition: Ischemic Stroke

    Sponsor: Ever Neuro Pharma GmbH

    Open on ClinicalTrials.gov ↗
  • NCT00911807 PHASE2 COMPLETED

    A Randomized, Double-Blind, Clinical Trial to Compare the Safety and Efficacy of Cerebrolysin and Aricept (Donepezil) and a Combination Therapy in Patients With Probable Alzheimer's Disease (AD)

    Condition: Alzheimer Disease

    Sponsor: Ever Neuro Pharma GmbH

    Open on ClinicalTrials.gov ↗
  • NCT01388738 PHASE3 COMPLETED

    Navigation Brain Stimulation (NBS) for Evaluation of the Neuroprotective Drug Efficiency in Patients After Ischemic Stroke.

    Condition: Stroke

    Sponsor: Clinical Institute of the Brain, Russia

    Open on ClinicalTrials.gov ↗
  • NCT01606111 PHASE4 TERMINATED

    A Randomized, Double-blind, Placebo-controlled Trial to Investigate Safety and Efficacy of Cerebrolysin in Patients With Traumatic Brain Injury

    Condition: Traumatic Brain Injury

    Sponsor: Ever Neuro Pharma GmbH

    Open on ClinicalTrials.gov ↗
  • NCT02116348 PHASE2 UNKNOWN

    Effect of Nerve Growth Factor (Cerebrolysin) Therapy on Neurodevelopment, Sleep Pattern and Quality of Life in Children With Traumatic Brain Injury and Cerebral Palsy

    Condition: Cerebral Palsy Children; Children With Traumatic Brain Injury; Mental Handicap; Delayed Speech Development

    Sponsor: Ain Shams University

    Open on ClinicalTrials.gov ↗
  • NCT02149875 PHASE1 COMPLETED

    A Comparison of Safety and Efficacy of Dl-3-n-butylphthalide and Cerebrolysin on Neurological and Behavioral Outcomes in Acute Ischemic Stroke: a Randomized, Double-blind Study.

    Condition: Acute Cerebral Stroke Within 12 Hours for the First Time

    Sponsor: Shanghai 6th People's Hospital

    Open on ClinicalTrials.gov ↗
  • NCT02581371 PHASE4 UNKNOWN

    Randomized, Double-blind, Placebo-controlled Study of the Effect of Cerebrolysin® (EVER Neuro Pharma GmbH, Austria) at the Level of Paresis of the Upper Limb When Used in Complex Therapy of Acute Ischemic Stroke

    Condition: Ischemic Stroke

    Sponsor: Clinical Institute of the Brain, Russia

    Open on ClinicalTrials.gov ↗
  • NCT03480698 COMPLETED

    C-REGS2 - a Registry Study to Observe Clinical Practices, Safety and Efficiency of Routine Use of Cerebrolysin in the Treatment of Patients with Moderate to Severe Neurological Deficits After Acute Ischaemic Stroke

    Condition: Acute Ischemic Stroke

    Sponsor: Ever Neuro Pharma GmbH

    Open on ClinicalTrials.gov ↗
  • NCT04124367 PHASE2 TERMINATED

    IMPULSE StIMulation of Brain Plasticity to Improve Upper Limb Recovery After StrokE A Prospective, Multi-center, Randomized, Double-blind Study to Assess Efficacy and Safety of Neuroplastic Intervention by Cerebrolysin and atDCS on Motor Function Recovery in Subacute and Chronic Stroke Patients

    Condition: Chronic Stroke; Subacute Stroke

    Sponsor: Ever Neuro Pharma GmbH

    Open on ClinicalTrials.gov ↗
  • NCT04751136 PHASE2 COMPLETED

    Phase (2) Clinical Trial Studying the Effect of Cerebrolysin on Physical and Mental Functions of Down Syndrome

    Condition: Down Syndrome

    Sponsor: Mansoura University Children Hospital

    Open on ClinicalTrials.gov ↗
  • NCT05288465 NA COMPLETED

    Hair Repigmentation in Patients Undergoing on Cerebrolysin Treatment for Neurological Diseases.

    Condition: Hair Problems

    Sponsor: Universidad Autonoma de Nuevo Leon

    Open on ClinicalTrials.gov ↗
  • NCT05821075 PHASE1 RECRUITING

    Comparative Study Between Prednisolone, Cerebrolysin in the Treatment of Bell's Palsy

    Condition: Bell Palsy

    Sponsor: October 6 University

    Open on ClinicalTrials.gov ↗
  • NCT05864677 NA UNKNOWN

    Efficacy of Cerebrolisin in the Prevention of Postoperative Delirium in Cardiac Surgery Patients

    Condition: Neurocognitive Disorders; Surgery-Complications; Critical Illness; Brain Damage; Cardiac Disease

    Sponsor: Medical University of Lublin

    Open on ClinicalTrials.gov ↗
  • NCT06052787 PHASE3 COMPLETED

    The Impact and Outcomes of Combined Cerebrolysin and Amantadine Sulfate Administration on Management of Patients With Traumatic Brain Injury in the ICU

    Condition: Traumatic Brain Injury

    Sponsor: Ain Shams University

    Open on ClinicalTrials.gov ↗
  • NCT06078215 PHASE4 UNKNOWN

    CERebrolysine Effect on Blood-brain Barrier / Endothelium Integrity During Reperfusion Therapy of acUte Ischemic Stroke (CERBERUS Study)

    Condition: Acute Ischemic Stroke

    Sponsor: Poznan University of Medical Sciences

    Open on ClinicalTrials.gov ↗
  • NCT06208540 PHASE4 COMPLETED

    Persistent Olfactory and Gustatory Dysfunctions Due to Different SARS-CoV-2 Variants: Clinical Characteristics and Treatment

    Condition: Post-covid-19 Persistent Smell and Taste Disorders

    Sponsor: Sherifa Ahmed Hamed

    Open on ClinicalTrials.gov ↗
  • NCT06429943 COMPLETED

    Cerebrolysin in Patients Diagnosed With SAH - an Observational Cohort Study (PILOT)

    Condition: SAH (Subarachnoid Hemorrhage)

    Sponsor: Pomeranian Medical University Szczecin

    Open on ClinicalTrials.gov ↗
  • NCT06677502 NA ENROLLING_BY_INVITATION

    The Usefulness of Cerebrolysin in Alleviating the Severity of Delirium in Critically Ill Patients

    Condition: Cognitive Impairment

    Sponsor: Medical University of Lublin

    Open on ClinicalTrials.gov ↗
  • NCT06897176 PHASE4 RECRUITING

    Effects of Cerebrolysin on Language Ability in Non-fluent Aphasia Patients After Stroke: A Randomized, Placebo-controlled, Double-blinded, Single Center Study

    Condition: Stroke

    Sponsor: Yonsei University

    Open on ClinicalTrials.gov ↗
  • NCT06899464 PHASE4 NOT_YET_RECRUITING

    Safety and Feasibility of Using Cerebrolysin in the Treatment of Primary Intracerebral Hemorrhage

    Condition: Intracerebral Hemorrhage; Hemorrhagic Stroke, Intracerebral; Hemorrhagic Stroke; Stroke

    Sponsor: Cardinal Stefan Wyszynski University

    Open on ClinicalTrials.gov ↗

Doses reported in studies

0 records
This is not a dosing guide. Entries below are historical metadata transcribed verbatim from a cited clinical-trial protocol, published study, or FDA-approved label. They describe what was administered in a specific study population under medical supervision — they are not recommendations, not common-use guidance, and may not be safe or appropriate outside the cited context. Doses widely discussed in community/anecdotal sources are not shown here; see the safety policy for why.

No study-protocol dose records have been curated for Cerebrolysin yet. Absence of records is not evidence of safety — many peptides lack adequate human-trial data in the first place.

Records here are populated from public sources only (ClinicalTrials.gov protocol summaries and FDA-approved labels) and must cite a verifiable source URL. They are not added from forum posts, vendor pages, anecdotal write-ups, or social media.

These entries describe what was studied. They do not tell you what to take, how to reconstitute anything, how to fill a capsule, how often to administer, or where to obtain a compound. If you are considering use of Cerebrolysin, those decisions belong with a licensed clinician working from the full label or trial record — not from this summary.

Why this page does not list a dose for self-use

The "Doses reported in studies" section above (when populated) describes what was administered in a cited study or label, under medical supervision, in a specific population. It is not a dosing guide for self-use. Separately, we do not publish anecdotal or community-reported dose ranges, administration methods, vial concentrations, or capsule masses for Cerebrolysin. Anecdotal figures for unapproved compounds are not harm-reduction data: they lack denominators for adverse events, cannot account for individual physiology or compound purity, and normalise unsupervised use. See the safety policy for the full reasoning.

If this compound has an FDA-approved label

If a label exists, the regulator-reviewed dosing and administration information is there — read it in the context of a prescriber's evaluation.

Questions worth bringing to a clinician

  • What is the evidence for this compound in someone with my history?
  • What are the realistic, regulator-reviewed alternatives?
  • What would you monitor, and what would make you stop?

If you have already taken a peptide and feel unwell: contact emergency services. In the United States, Poison Control is reachable 24/7 at 1-800-222-1222. Do not wait for a community thread.

Research peptides are not substitutes for medical care. If you are considering any peptide for health purposes, speak with a board-certified physician or endocrinologist first.